← Back to All Filings

Avidity Bio CEO Awarded Stock, Sells $1.1M for Tax Withholding

Low SignificanceDecember 19, 2025 at 8:32:43 AM EST

Avidity Biosciences, Inc.

$RNA4CIK: 0001599901

Subscribe to track RNA

Premium users can add ticker alerts and receive realtime notification updates.

Filing Summary

Avidity Bio CEO Awarded Stock, Sells $1.1M for Tax Withholding

Company: Avidity Biosciences, Inc. (RNA) Form: 4 | Filed: 2025/12/19 Significance: Low

Insider: Boyce Sarah Title: President and CEO | Relationship: Director, Officer

Transactions: • Award (A): Acquired 31,000 shares at $0.00 from PSU vesting. • Tax Sale (F): Disposed of 15,742 shares at $71.87 to cover taxes, valued at ~$1.13M. • Gift (G): Donated 29,159 shares. • Owned After: 291,970 shares

Key Insight: These are non-discretionary transactions. The sale was automatic to cover tax obligations from a stock award, not a voluntary reduction of holdings. The gift is a non-market charitable donation.

Market Context: With a market cap of $10.67B, the $1.13M tax sale represents a negligible 0.01% of the company's value, indicating low market impact.

Comprehensive Analysis

SEC Filing Analysis: Avidity Biosciences, Inc. (RNA)

Executive Summary

  • Trading Significance: Low
  • Key Takeaway: The President and CEO of Avidity Biosciences received a stock award and subsequently disposed of shares for tax withholding and made a charitable gift. These are non-discretionary, non-open market transactions with minimal market significance.
  • Market Impact: Neutral. The transactions are routine compensation-related events and do not signal a change in the insider's outlook on the company.

Company Information

FieldValue
CompanyAvidity Biosciences, Inc.
Ticker SymbolRNA
CIK0001599901
IndustryPHARMACEUTICAL PREPARATIONS [2834]

Insider Information

FieldValue
NameBoyce Sarah
CIK0001629383
Title/PositionPresident and CEO
RelationshipDirector, Officer

Transaction Details

This filing reports three related transactions:

  1. Stock Award (Code A): Acquisition of 31,000 shares of Common Stock at $0.00 upon the vesting of Performance-Based Restricted Stock Units (PSUs) on 2025-12-17.
  2. Tax Withholding (Code F): Disposition of 15,742 shares of Common Stock at $71.87 per share on 2025-12-17. This was to satisfy tax withholding obligations related to the PSU vesting, with a total value of approximately $1,131,485.
  3. Gift (Code G): Disposition of 29,159 shares of Common Stock at $0.00 as a gift to a Donor Advised Fund on 2025-12-18.
FieldValue (for Tax Withholding)
Form Type4
Transaction Date2025-12-17
Transaction CodeF
Security TypeCommon Stock
Shares Involved15,742
Price Per Share$71.87
Total Value$1,131,484.54
Shares Owned After291,970 (after all transactions)
Ownership TypeDirect

Financial Impact Assessment

Transaction Materiality

MetricValue
Transaction Value$1,131,484.54 (Tax Sale)
% of Market Cap0.01%
Shares TransactedN/A (Shares Outstanding not provided)
% of Shares OutstandingN/A
Post-Transaction Ownership291,970 shares
Materiality AssessmentLow

Impact Evaluation

  • Market Cap Context: Avidity Biosciences has a large-cap valuation of $10.67 billion. The $1.13 million tax-related sale is immaterial, representing just 0.01% of the company's market capitalization.
  • Transaction Significance: The significance is low. The primary event is the vesting of a stock award, a form of executive compensation. The subsequent sale (Code F) is an automatic transaction to cover taxes and does not reflect a discretionary decision by the insider to sell shares. The gift (Code G) is a non-market charitable act.

Market Impact Analysis

Stock Impact Prediction

  • Direction: Neutral
  • Reasoning: The transactions are non-discretionary and related to executive compensation and tax planning. They do not provide any new information about the insider's sentiment towards the company's future prospects.

Volume & Sentiment

  • Expected Volume Impact: Minimal. These are not open-market trades that would influence trading volume.
  • Sentiment Indicator: Neutral. The filing is informational and relates to standard executive compensation procedures.

Additional Context

Transaction Notes

  • Footnote F1: Confirms the acquisition of 31,000 shares was from the vesting of PSUs.
  • Footnote F2: Explicitly states the 15,742 share disposition was to cover tax withholding obligations.
  • Footnote F3: Identifies the 29,159 share disposition as a gift to a Donor Advised Fund.
Topics:#SECFiling#InsiderTrading#Form4#RNA#AvidityBiosciences#CEO#StockAward#Biotech#StockMarket#MarketAnalysis

Get Real-Time Alerts

Join our community to receive instant notifications when high-significance filings are published

Important Disclaimer

This content is drawn from public SEC filings and may contain errors. It is for informational purposes only and is not investment, legal, or tax advice.

Nothing here is a recommendation to buy, sell, or hold any security. Do your own due diligence.